Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Transplantation and Cellular Therapy|December 27, 2025
Validation of the CARE-BMT Score and Proposal of a Modified Risk Model with Post-Transplant Cyclofosfamide for Predicting Early Cardiac Events after Allo-HCTArnau Torrent, Enric Cascos, Esther Carcelero, et al.
Cancers|December 11, 2022
Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53-Mutated Metastatic Colorectal CancerSara Lahoz, Adela Rodríguez, Laia Fernández, et al.
Pharmaceuticals (Basel, Switzerland)|December 23, 2023
At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible ProgramSonia Ruiz-Boy, Alexandra Pedraza, Marta Prat, et al.
Pharmaceuticals (Basel, Switzerland)|December 23, 2022
Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant CyclophosphamideDaniel N Marco, María Queralt Salas, Gonzalo Gutiérrez-García, et al.
British Journal of Haematology|February 21, 2026
Avatrombopag for post-transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single-centre retrospective studyCristian Alberdi-Lema, Beatriz García-Villaronga, Thais Linzodo-López, et al.
Pharmaceuticals (Basel, Switzerland)|May 25, 2024
Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell TransplantationDaniel N Marco, Mònica Molina, Ana-María Guio, et al.
Bone Marrow Transplantation|August 8, 2024
Safety and efficacy of G-CSF after allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide: clinical and in vitro examination of endothelial activationSilvia Escribano-Serrat, Alexandra Pedraza, María Suárez-Lledó, et al.
The Oncologist|September 30, 2024
Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?Sandra Castaño-Díez, José Ramón Álamo, Mònica López-Guerra, et al.
Experimental Hematology & Oncology|April 26, 2025
Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD studyInes Zugasti, Monica Lopez-Guerra, Sandra Castaño-Díez, et al.
Pageof 2